Premium
Interleukin‐27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro
Author(s) -
Zolochevska Olga,
DiazQuiñones Adriana O.,
Ellis Jayne,
Figueiredo Marxa L.
Publication year - 2013
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.24265
Subject(s) - autocrine signalling , cancer research , prostate cancer , paracrine signalling , tumor microenvironment , biology , cytokine , crosstalk , microbiology and biotechnology , downregulation and upregulation , bone metastasis , immune system , immunology , cancer , cell culture , receptor , gene , biochemistry , genetics , physics , optics
Prostate cancer is frequently associated with bone metastases, where the crosstalk between tumor cells and key cells of the bone microenvironment (osteoblasts, osteoclasts, immune cells) amplifies tumor growth. We have explored the potential of a novel cytokine, interleukin‐27 (IL‐27), for inhibiting this malignant crosstalk, and have examined the effect of autocrine IL‐27 on prostate cancer cell gene expression, as well as the effect of paracrine IL‐27 on gene expression in bone and T cells. In prostate tumor cells, IL‐27 upregulated genes related to its signaling pathway while downregulating malignancy‐related receptors and cytokine genes involved in gp130 signaling, as well as several protease genes. In both undifferentiated and differentiated osteoblasts, IL‐27 modulated upregulation of genes related to its own signaling pathway as well as pro‐osteogenic genes. In osteoclasts, IL‐27 downregulated several genes typically involved in malignancy and also downregulated osteoclastogenesis‐related genes. Furthermore, an osteogenesis‐focused real‐time PCR array revealed a more extensive profile of pro‐osteogenic gene changes in both osteoblasts and osteoclasts. In T‐lymphocyte cells, IL‐27 upregulated several activation‐related genes and also genes related to the IL‐27 signaling pathway and downregulated several genes that could modulate osteoclastogenesis. Overall, our results suggest that IL‐27 may be able to modify interactions between prostate tumor and bone microenvironment cells and thus could be used as a multifunctional therapeutic for restoring bone homeostasis while treating metastatic prostate tumors. J. Cell. Physiol. © 2012 Wiley Periodicals, Inc.